NEW YORK, October 12, 2009 – LawFuel.com – Kaye Scholer LLP represented Novartis in an agreement with Vanda Pharmaceuticals Inc. for exclusive US and Canadian rights to FanaptTM (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia.
The Kaye Scholer team included Partner Adam H. Golden, Counsel Lily J. Wound and Associate Sandra J. Liubicic.
About Kaye Scholer
Kaye Scholer refers to Kaye Scholer LLP and its affiliates, with offices in Chicago, Frankfurt, London, Los Angeles, New York, Shanghai, Washington, DC, and West Palm Beach. Founded in New York City in 1917, Kaye Scholer represents public and private companies, governmental entities, financial institutions, and other organizations in matters around the world. Additional information is available on the firm’s website: www.kayescholer.com.